Pharma Sector Q3 Review: Lupin, Cipla Lead As Chronic Therapies Outshine Acute Drugs
India's top pharmaceutical companies delivered a mixed performance in the third quarter of fiscal 2025, with revenue growing 9% year-on-year, while Ebitda and net profit rose 13% and 17%, respectively, according to Nuvama Institutional Equities.
Lupin Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Zydus Lidesciences Ltd. delivered strong revenue and profit growth in the December quarter, beating analyst expectations, and are the brokerages "top performers." On the other hand, Dr. Reddy's Laboratories Ltd., Natco Pharma Ltd., Orchid Pharma Ltd., and Biocon Ltd. underperformed, with the first two reporting significant declines in profitability.
The domestic market saw a 7% rise in sales, driven by gains in cardiac, oncology, and dermatology therapies, even as anti-infective and respiratory drugs underperformed. Nuvama found that Sun Pharma, Cipla, Lupin, Torrent, and Ajanta benefitted from the shift towards chronic treatments, while Alkem struggled due to weakness in anti-infective sales.
In North America, revenues declined 3% both on a yearly basis and sequential basis, weighed down by softer generic Revlimid sales and increased competition. However, contract development and manufacturing businesses performed well, led by strong growth at Divi's Laboratories Ltd., while contract research organisations remained under pressure, the brokerage noted.
R&D spending rose 9% year-on-year, accounting for 6.4% of total sales, despite Sun Pharma scaling back investments. Zydus, Lupin, and Dr. Reddy's Laboratories ramped up research efforts, positioning themselves for future product launches, including semaglutide or diabetes medicines in calendar year 2026.
With the US flu season expected to be strong, Lupin and Aurobindo Pharma Ltd. are likely to benefit in the next quarter. Sun Pharma, supported by lower R&D spending and seasonal demand, could also post strong fourth quarter results, according to Nuvama. However, the anticipated decline in gRevlimid sales by mid-FY26 remains a key concern for generic drugmakers, the note said.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.